Internal Medicine · Tahlequah, OK
NPI
1073615324
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
1373 E Boone St Ste 2300
Tahlequah, OK, 74464
Phone (918) 207-0025
Groups this clinician bills Medicare through
Medicare paid, 2024
$22K
376 services
Medicare patients, 2024
284
Average age 70
Drug cost, 2024
$4.9M
1,427 prescriptions
Company payments, 2025
$672
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Prashant Kaushik was code 99213 (office e&m - established), 199 times for 162 patients. In total Prashant Kaushik billed 376 services in 11 codes, and Medicare paid $22K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 199 | 162 | $43.48 | $8,653 |
| 99214 Office E&M - Established | Facility | 110 | 98 | $67.40 | $7,414 |
| 99204 Office E&M - New | Facility | 36 | 36 | $91.31 | $3,287 |
| 99203 Office E&M - New | Facility | 11 | 11 | $48.89 | $538 |
By year: 2022 $45K for 607 services; 2023 $25K for 415 services; 2024 $22K for 376 services.
Medicare prescription drug claims, 2024
In 2024, the drug Prashant Kaushik prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 486 prescriptions and refills. In total Prashant Kaushik wrote 1,427 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 486 | 1,129 | 148 | $15K |
| Humira(Cf) Pen Adalimumab | 224 | 231 | 44 | $1.7M |
| Rinvoq Upadacitinib | 152 | 166 | 21 | $1.0M |
| Prednisone Generic | 96 | 186 | 35 | $485 |
| Hadlima(Cf) Pushtouch Adalimumab-Bwwd | 58 | 60 | 17 | $66K |
| Cosentyx Sensoready Pen Secukinumab | 40 | 40 | Under 11 | $296K |
| Enbrel Sureclick Etanercept | 38 | 55 | Under 11 | $353K |
| Actemra Actpen Tocilizumab | 27 | 27 | Under 11 | $87K |
| Methotrexate Methotrexate Sodium | 25 | 69 | Under 11 | $1,103 |
| Benlysta Belimumab | 25 | 25 | Under 11 | $131K |
| Orencia Clickject Abatacept | 24 | 26 | Under 11 | $159K |
| Cosentyx Sensoready (2 Pens) Secukinumab | 23 | 27 | Under 11 | $166K |
| Xeljanz Xr Tofacitinib Citrate | 20 | 20 | Under 11 | $109K |
| Humira(Cf) Adalimumab | 19 | 19 | Under 11 | $125K |
| Humira Pen Adalimumab | 19 | 19 | Under 11 | $125K |
Brand drugs: 769 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Prashant Kaushik $672 ($672 in general payments such as food, travel and fees) from 4 companies. The largest payer was Vertex Pharmaceuticals Incorporated with $400.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.